---
title: "GAMLSS versus Linear Regression for Neuropsychological Norms: Comparable Clinical Outcomes"
id: "medrxiv-14-smooth-curves-similar-conclusions-comparing-linear-regression-and-gamlss"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-14-smooth-curves-similar-conclusions-comparing-linear-regression-and-gamlss"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.01.26361590v1?rss=1"
published_at: "2026-09-04T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# GAMLSS versus Linear Regression for Neuropsychological Norms: Comparable Clinical Outcomes
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-14-smooth-curves-similar-conclusions-comparing-linear-regression-and-gamlss
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.01.26361590v1?rss=1)
- **Published At:** 2026-09-04T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study compared traditional **linear regression (LR)**–based normative scores with norms derived from **Generalized Additive Models for Location, Scale and Shape (GAMLSS)** for a brief cognitive battery used in the Norwegian Dementia Disease Initiation (DDI) cohort. - Norms were constructed for the CERAD word list test (including delayed recall), Trail Making Test (TMT) A and B, FAS phonemic fluency, and VOSP Silhouettes using the same normative samples as the original LR norms. - Expected low-score frequencies and empirical base rates were evaluated in a normative subsample (n = 131); clinical implications were assessed in the DDI clinical cohort (n = 643). - **GAMLSS** produced lower frequencies of low scores compared with LR norms, an effect largely driven by the **CERAD delayed recall** measure. - Overall concordance between the two normative methods was high (kappa = 0.91), with 4.2% of classifications discordant between approaches. - Two-year diagnostic stability and change in the clinical cohort were broadly similar regardless of whether LR or GAMLSS norms were applied. - Cerebrospinal fluid (CSF) biomarker profiles did not clearly favor either normative method when relating biomarker status to cognitive classifications. - Authors conclude **GAMLSS** more accurately models bounded and non-normal score distributions, but downstream clinical differences in classification and prognostic indicators were modest in this dataset. - Ethical approvals were obtained for the DDI, TronderBrain, and Gothenburg MCI studies; all participants provided written informed consent. Data are not freely available due to ethical restrictions. - Funding sources included the EU Joint Programme – Neurodegenerative Disease Research, The Research Council of Norway, and Helse Nord.
## Clinical Analysis & Structured Key Points
Smooth Curves, Similar Conclusions? Comparing Linear Regression and GAMLSS Neuropsychological Norms | medRxiv Skip to main content Smooth Curves, Similar Conclusions? Comparing Linear Regression and GAMLSS Neuropsychological Norms View ORCID Profile Bjorn-Eivind Kirsebom , Ingrid Myrvoll Lorentzen , Jacob Espenes , Ingvild Vollo Eliassen , View ORCID Profile Fernando Gonzalez-Ortiz , Anders Wallin , Knut Waterloo , Marie Eckerstrom , Goril Rolfseng Grontvedt , Erik Hessen , Tormod Fladby doi: https://doi.org/10.64898/2026.09.01.26361590 Bjorn-Eivind Kirsebom 1 The Arctic University of Norway, Tromso, Norway; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Bjorn-Eivind Kirsebom For correspondence: bjorn-eivind.kirsebom{at}unn.no Ingrid Myrvoll Lorentzen 1 The Arctic University of Norway, Tromso, Norway; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jacob Espenes 2 Oslo University Hospital, Oslo, Norway; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ingvild Vollo Eliassen 3 Akershus University Hospital, Lorenskog, Norway; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Fernando Gonzalez-Ortiz 4 Gothenburg University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Fernando Gonzalez-Ortiz Anders Wallin 5 University of Gothenburg, Gothenburg, Sweden.; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Knut Waterloo 1 The Arctic University of Norway, Tromso, Norway; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Marie Eckerstrom 5 University of Gothenburg, Gothenburg, Sweden.; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Goril Rolfseng Grontvedt 6 University Hospital of Trondheim, Trondheim, Norway. Find this author on Google Scholar Find this author on PubMed Search for this author on this site Erik Hessen 3 Akershus University Hospital, Lorenskog, Norway; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tormod Fladby 3 Akershus University Hospital, Lorenskog, Norway; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Objective: Regression-based normative approaches are widely used in neuropsychology but often rely on score transformations to satisfy model assumptions. We compared previously published linear regression (LR)-based norms with norms derived using Generalized Additive Models for Location, Scale and Shape (GAMLSS) for the brief cognitive battery used in the Norwegian Dementia Disease Initiation (DDI) cohort. Method: GAMLSS norms were developed using the same normative samples as the original LR norms for the Consortium to Establish a Registry for Alzheimers Disease (CERAD) word list test, Trail Making Test (TMT) A and B, FAS phonemic fluency, and Visual Object and Space Perception Battery (VOSP) Silhouettes. Expected low-score frequencies and empirical base rates were assessed in a normative subsample (n = 131). Clinical implications were evaluated in the DDI clinical cohort (n = 643) using Mild Cognitive Impairment (MCI) classification, two-year diagnostic stability and change, and cerebrospinal fluid (CSF) biomarkers. Results: Compared with LR norms, GAMLSS yielded lower frequencies of low scores, primarily driven by CERAD delayed recall. Nevertheless, concordance between approaches was high (kappa = 0.91), with only 4.2% discordant classifications. Two-year diagnostic stability and change were broadly similar across approaches, and CSF biomarker profiles did not clearly favor either normative method. Conclusions: GAMLSS provided a more faithful representation of neuropsychological score distributions, particularly for bounded and non-normal outcomes. However, downstream clinical differences were modest in this setting, suggesting that well-calibrated LR norms may remain robust for clinical classification. Competing Interest Statement BEK has served as a consultant for Biogen and Eli-Lilly, and on medical advisory boards for Eisai and Eli-Lilly. FG-O has served on scientific advisory boards and/or as a consultant for AIBL-Tecan. TF has served as a consultant and at the advisory boards for Biogen, Novo Nordisk, Eli Lilly, Roche and Eisai. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The DDI, TronderBrain, and Gothenburg MCI studies were approved by their respective regional or local research ethics committees. All participants provided written informed consent prior to participation, including information regarding the right to withdraw and the potential risks and benefits of participation. All study procedures were conducted in accordance with the ethical principles of the Declaration of Helsinki (1964, revised 2013) and applicable national regulations, including the Norwegian Health Research Act where relevant. All datasets used in the present study were de-identified prior to analysis, with participants represented only by study-specific identification codes; linkage keys and directly identifying information were not included in the analytic datasets. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Due to ethical restrictions, the data generated in the present study are not freely available for sharing. Funder Information Declared The EU Joint Programme – Neurodegenerative Disease Research The Research Council of Norway, https://ror.org/00epmv149 Helse Nord , HNF1665-23 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 04, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Smooth Curves, Similar Conclusions? Comparing Linear Regression and GAMLSS Neuropsychological Norms Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Smooth Curves, Similar Conclusions? Comparing Linear Regression and GAMLSS Neuropsychological Norms Bjorn-Eivind Kirsebom , Ingrid Myrvoll Lorentzen , Jacob Espenes , Ingvild Vollo Eliassen , Fernando Gonzalez-Ortiz , Anders Wallin , Knut Waterloo , Marie Eckerstrom , Goril Rolfseng Grontvedt , Erik Hessen , Tormod Fladby medRxiv 2026.09.01.26361590; doi: https://doi.org/10.64898/2026.09.01.26361590 Share This Article: Copy Citation Tools Smooth Curves, Similar Conclusions? Comparing Linear Regression and GAMLSS Neuropsychological Norms Bjorn-Eivind Kirsebom , Ingrid Myrvoll Lorentzen , Jacob Espenes , Ingvild Vollo Eliassen , Fernando Gonzalez-Ortiz , Anders Wallin , Knut Waterloo , Marie Eckerstrom , Goril Rolfseng Grontvedt , Erik Hessen , Tormod Fladby medRxiv 2026.09.01.26361590; doi: https://doi.org/10.64898/2026.09.01.26361590 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (615) Allergy and Immunology (896) Anesthesia (327) Cardiovascular Medicine (4777) Dentistry and Oral Medicine (476) Dermatology (410) Emergency Medicine (645) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1617) Epidemiology (15853) Forensic Medicine (32) Gastroenterology (1196) Genetic and Genomic Medicine (6996) Geriatric Medicine (727) Health Economics (1059) Health Informatics (4999) Health Policy (1428) Health Systems and Quality Improvement (1742) Hematology (583) HIV/AIDS (1338) Infectious Diseases (except HIV/AIDS) (16251) Intensive Care and Critical Care Medicine (1163) Medical Education (665) Medical Ethics (151) Nephrology (721) Neurology (7208) Nursing (365) Nutrition (1074) Obstetrics and Gynecology (1233) Occupational and Environmental Health (1002) Oncology (3581) Ophthalmology (1039) Orthopedics (394) Otolaryngology (448) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1782) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5846) Public and Global Health (9705) Radiology and Imaging (2392) Rehabilitation Medicine and Physical Therapy (1436) Respiratory Medicine (1245) Rheumatology (635) Sexual and Reproductive Health (769) Sports Medicine (577) Surgery (769) Toxicology (107) Transplantation (303) Urology (287)
## Related Clinical Research

- [VR Headset Pupillometry Detects RAPD and Pathological Anisocoria: Study Results](https://medichelpline.com/clinical-feed/medrxiv-1-pupil-symmetry-and-swinging-light-test-performed-with-vr-headset-for-detection.md)
- [After Ultragenyx Angelman drug failure, experts say other antisense therapies still hold promise](https://medichelpline.com/clinical-feed/stat-news-1-stat-after-failure-of-angelman-syndrome-drug-experts-see-hope-in-other.md)
- [SniffCell: Cell-type-resolved somatic variant discovery from bulk long-read sequencing](https://medichelpline.com/clinical-feed/medrxiv-11-cell-type-resolved-somatic-variant-discovery-from-bulk-long-read-sequencing.md)
- [Diurnal and Seasonal Variation in Brain mu-Opioid and Dopamine D2 Receptor Signaling](https://medichelpline.com/clinical-feed/biorxiv-6-diurnal-and-seasonal-regulation-of-brain-mu-opioid-and-dopamine-d2-receptor.md)
- [FDA approves Zanvastro, the first disease-modifying drug for Alexander disease](https://medichelpline.com/clinical-feed/stat-news-0-stat-ionis-wins-fda-approval-for-first-drug-for-alexander-disease-a-rare-and.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.